US20080057116A1 - Emu Oil and Fruit Composition - Google Patents

Emu Oil and Fruit Composition Download PDF

Info

Publication number
US20080057116A1
US20080057116A1 US11/572,851 US57285105A US2008057116A1 US 20080057116 A1 US20080057116 A1 US 20080057116A1 US 57285105 A US57285105 A US 57285105A US 2008057116 A1 US2008057116 A1 US 2008057116A1
Authority
US
United States
Prior art keywords
composition
cherries
emu oil
fruit
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/572,851
Other languages
English (en)
Inventor
Raymond Pleva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/572,851 priority Critical patent/US20080057116A1/en
Publication of US20080057116A1 publication Critical patent/US20080057116A1/en
Priority to US12/486,327 priority patent/US7939107B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the invention relates to compositions suitable for topical application to human skin and suitable for ingesting, and, more particularly, to natural compositions comprising emu oil and various fruits.
  • Emu oil also known as kalaya oil
  • Emu oil is rendered from the bird's fat. It is used in cosmetics and cosmetic related items, including wrinkle retarding emollients, cosmetic bases and moisturizers for the face and body. It exhibits certain surface penetrating characteristics that can increase the penetration of compositions through human skin. It is therapeutically used in methods for lowering cholesterol, triglycerides and low density lipoproteins and increasing high density lipoproteins. It is believed by many to prevent and treat allergies, prevent scarring, treat headaches, prevent nosebleeds, treat cold and flu symptoms, and relieve discomfort associated with menstruation. It is known to be ingested by spoon, dropper, tablet, gelatin capsule, time release capsules, and as a food additive. It can be administered in the form of emulsions, suspensions, and powders. Topically, it can be administered in creams, lotions, oils, powders, and gels.
  • Some fruits are known to be high in anti-oxidants and have proven effective in improving health. Blueberries, pomegranates, plums, cranberries, black chokeberries ( sanbucus nigra ), black elderberries, and cherries are all relatively high in anti-oxidants.
  • cherries are known to provide a variety of additional health benefits.
  • Tart cherries prunus cerasus
  • Montmorency and Balaton varieties have been shown to be a particularly good source of bioflavonoids in addition to anti-oxidants.
  • anthocyanins from cherries are known to be an effective anti-inflammatory agent.
  • Melatonins from cherries are known to be an effective anti-oxidant. Both have been found to reduce cancers.
  • Cherries are also believed to assist in the proper balancing of certain hormones. Indeed, cherries are commonly called “the healing fruit.”
  • compositions comprising emu oil and processed whole fruit, preferably a fruit selected from the group including blueberries, pomegranates, plums, cranberries, black chokeberries, black elderberries, and cherries.
  • the composition includes emu oil and whole cherries or at least one substance extracted from whole cherries.
  • the substance is from the group consisting of anthocyanins, melatonins, phenolics, and flavonoids.
  • the invention comprises a composition formed of emu oil and fruit.
  • the emu oil is processed in that it is refined to remove impurities, discoloration, etc.
  • a preferred process for refining emu oil is commonly termed “cold rendering” in which the temperature of the oil is not raised too high so as to make it unstable.
  • a preferred emu oil for use in the present invention can be obtained from L. B. Processors LLC, 1846 Mosley Ferry Rd., Chapmansboro, Tenn. 37035. It is believed that any other emu oil having a similar composition is substantially equally effective for purposes of the invention.
  • a preferred fruit includes cherries, and preferably tart cherries of the Montmorency or Balaton varieties. Sweet cherries can also provide similar benefits.
  • the cherries are preferably provided in the form of a cherry concentrate.
  • the cherry concentrate is made in a conventional manner by squeezing and cooking down whole cherries preferably to a concentration of 68 brix.
  • the term “brix” is used in its conventional meaning of a unit of measure of sucrose (the percent of sugar in 100 g of cane sugar solution).
  • a concentration greater or lesser than 68 brix is acceptable, preferably within a range of plus or minus seven brix.
  • Montmorency cherries it takes about 88 lbs. of cherries to render 1 gallon of cherry concentrate.
  • Cherry concentrates within the preferred range of concentration are commercially available.
  • cherries is a freeze dried powder manufactured by a vacuum freeze drying process.
  • a commercial source of freeze dried red tart cherry powder is Crystals International, Inc., 600 West Dr. M. L. King, Jr. Blvd., Plant City, Fla. This product contains 70% red Tart cherry juice concentrate.
  • Cherry powder can also be made in spray dry, drum dry and pan dry processes.
  • Other acceptable forms of cherries include cherry purees and Elliott cherries (similar to a puree, but with bigger pieces of whole cherries).
  • the emu oil and cherries are combined to form a cream, oil, or lotion for topical use on human skin.
  • a preferred composition will include a range of 1% to 20% emu oil, and 2% to 15% cherries, by weight. All of the natural health benefits of the cherries such as those found in specified compounds including anthocyanins and melatonins are transported subcutaneously by the emu oil's penetration of the skin. It may be advisable to provide other compounds in the composition to enhance solubility and viscosity characteristics. Such compounds might include water, glycerin, and well known emulsions that are common to cosmetics, creams and oils.
  • emu oil and cherries are reduced to a form for internal administration.
  • a form for internal administration is an oral administration comprising a gelatin capsule of the composition.
  • Other examples include a powdered form of composition in a capsule, or a dried form of the composition pressed into a tablet.
  • a preferred composition for oral administration will include a range of 1% to 35% emu oil, and 1% to 45% cherries, by weight.
  • the composition can be administered systemically such as by subcutaneous or intramuscular injection. It can also be administered orally by solution, or emulsion with fewer side effects.
  • compositions improves digestion, retards the aging process, reduces the inflammation of arthritis and gout, protects against certain types of cancer and heart disease, assists in stabilizing and balancing hormones, neutralizes free radicals, reduces short-term memory loss, aids in combating stress, reduces high strain and fatigue, reduces LDL cholesterol, improves the bodies of certainty in rhythms and natural sleep patterns, and maintains a long, stable shelf life, all without disruptive side effects.
  • the invention also encompasses compositions comprising emu oil and active ingredients extracted from whole cherries, such as cherry-derived anthocyanins and melatonins.
  • composition can take the form of creams, pills, gelatin capsules, massage oils, lotions, gels, shampoos, soaps, conditioners, sprays, solids, and powders. It is believed that with certain emulsions well known to those of ordinary skill in the art, such products as car cleaners and floor cleaners can benefit from the composition. As well, it is believed that pet food can be enhanced by incorporating a combination of emu oil and fruit.
  • cherries can be used in combination with emu oil for the particular benefits afforded by those fruits.
  • fruits known to be high in anti-oxidants have proven effective.
  • Blueberries, pomegranates, plums, cranberries, black chokeberries ( sanbucus nigra ), and black elderberries in concentrate form, in extracts, or in powders can be used instead of cherries. But they can also be used in addition to cherries.
  • a sample formula will contain one part cherry concentrate, one part emu oil, one part omega 3 fish oil (pharmaceutical grade/toxin free), one part certified organic top grade flaxseed oil, and one part CoQ10. If taste must be enhanced, more cherry concentrate can be added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
US11/572,851 2004-07-28 2005-07-28 Emu Oil and Fruit Composition Abandoned US20080057116A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/572,851 US20080057116A1 (en) 2004-07-28 2005-07-28 Emu Oil and Fruit Composition
US12/486,327 US7939107B2 (en) 2004-07-28 2009-06-17 Emu oil and fruit composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52196504P 2004-07-28 2004-07-28
US59385205P 2005-02-18 2005-02-18
US11/572,851 US20080057116A1 (en) 2004-07-28 2005-07-28 Emu Oil and Fruit Composition
PCT/US2005/026782 WO2006015119A2 (fr) 2004-07-28 2005-07-28 Composition d'huile d'emeu et de fruit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026782 A-371-Of-International WO2006015119A2 (fr) 2004-07-28 2005-07-28 Composition d'huile d'emeu et de fruit

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/486,327 Continuation US7939107B2 (en) 2004-07-28 2009-06-17 Emu oil and fruit composition

Publications (1)

Publication Number Publication Date
US20080057116A1 true US20080057116A1 (en) 2008-03-06

Family

ID=35787823

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/572,851 Abandoned US20080057116A1 (en) 2004-07-28 2005-07-28 Emu Oil and Fruit Composition
US12/486,327 Active 2025-10-12 US7939107B2 (en) 2004-07-28 2009-06-17 Emu oil and fruit composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/486,327 Active 2025-10-12 US7939107B2 (en) 2004-07-28 2009-06-17 Emu oil and fruit composition

Country Status (9)

Country Link
US (2) US20080057116A1 (fr)
EP (1) EP1771185A4 (fr)
JP (1) JP2008508301A (fr)
CN (1) CN101065132A (fr)
AU (1) AU2005269382A1 (fr)
CA (1) CA2574968C (fr)
MX (1) MX2007001098A (fr)
RU (1) RU2007103125A (fr)
WO (1) WO2006015119A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192126A1 (en) * 2006-04-12 2009-07-30 John Casey Oral Composition Comprising a Polyunsaturated Fatty Acid and Salicylic Acid for Obtaining an Antiinflammatory Effect in Skin
US8562976B2 (en) 2004-01-22 2013-10-22 University Of Miami Co-enzyme Q10 formulations and methods of use
US20150231060A1 (en) * 2013-03-14 2015-08-20 3 In 1 Dental Pllc Compositions for treatment of xerostomia and for tooth treatment
US20170304187A1 (en) * 2011-06-08 2017-10-26 Scott A. Weisenfluh EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections
US9896731B2 (en) 2009-05-11 2018-02-20 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US9901542B2 (en) 2013-09-04 2018-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
US10376477B2 (en) 2011-04-04 2019-08-13 Berg Llc Method of treating or preventing tumors of the central nervous system
US10668028B2 (en) 2008-04-11 2020-06-02 Berg Llc Methods and use of inducing apoptosis in cancer cells
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196298A1 (en) * 2005-05-31 2007-08-23 Kostick Richard H Cosmetic and dermatological formulations with natural pigments and methods of use
US20080089941A1 (en) * 2006-06-01 2008-04-17 Mower Thomas E Fucoidan compositions and methods
US7494674B2 (en) 2006-09-22 2009-02-24 Lapointe Andrew T Nutraceutical with tart cherries and method of treatment therewith
CN102389378B (zh) * 2011-11-23 2012-12-12 天津郁美净集团有限公司 一种用于化妆品的复合油脂微乳液及其制备方法
CN106138717A (zh) * 2015-03-25 2016-11-23 张爱民 一种用于冰疗的药膏及其制备使用方法
JP2019510036A (ja) 2016-03-31 2019-04-11 ゴジョ・インダストリーズ・インコーポレイテッド プロバイオティクス／プレバイオティクス有効成分を含む清浄剤組成物
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US20190175680A1 (en) * 2016-09-07 2019-06-13 Nanosmart Fruit, Llc Compositions comprising nanoparticles derived from whole fruit
AU2017365019A1 (en) 2016-11-23 2019-07-11 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472713A (en) * 1994-11-23 1995-12-05 Elf Resources, Inc. Therapeutic uses of emu oil
US5670200A (en) * 1992-12-01 1997-09-23 Pleva; Raymond M. Cherry-containing meat product and method of making the same
US6103246A (en) * 1993-06-03 2000-08-15 Tisdale; Carrie J. Creams and lotions containing emu oil
US6342208B1 (en) * 1996-08-02 2002-01-29 Plum Kerni Produktion A/S Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals
US20020055562A1 (en) * 1998-10-29 2002-05-09 Butuc S. Gina Gel compositions
US6407141B1 (en) * 1995-11-15 2002-06-18 Francis J. Hart Oxalic acid or oxalate compositions and methods for vascular disorders, diseases, and calcerous conditions
US20030031724A1 (en) * 2001-05-16 2003-02-13 Frank Orthoefer Anti-inflammatory composition and method of using same
US6531126B2 (en) * 1999-08-26 2003-03-11 Ganeden Biotech, Inc. Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US6534086B1 (en) * 2000-03-06 2003-03-18 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20030175332A1 (en) * 2001-07-31 2003-09-18 Brown Harold G Methods of preventing or treating diseases and conditions using complex carbohydrates
US20050123479A1 (en) * 2002-03-01 2005-06-09 Antonio Ferrante Therapeutic properties of oils
US20050266064A1 (en) * 2004-05-29 2005-12-01 Mccarthy Kathryn J Cosmetic compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652007A (en) * 1992-12-01 1997-07-29 Pleva; Raymond M. Method of making a cured cherry-containing meat product
WO1998050005A1 (fr) 1997-05-09 1998-11-12 Medlogic Global Corporation Compositions pour applications cosmetiques
WO2000026285A1 (fr) 1998-10-29 2000-05-11 Penreco Compositions de gel
US20060073211A1 (en) * 2001-06-18 2006-04-06 Michael Marenick Cellulite formulation containing whole egg
US6773718B2 (en) * 2001-11-15 2004-08-10 3M Innovative Properties Company Oil absorbent wipe with rapid visual indication
AU2002950308A0 (en) * 2002-07-23 2002-09-12 Phoenix Eagle Company Pty Ltd Topically applied composition
US20080032032A1 (en) * 2006-08-01 2008-02-07 Pleva Raymond M Cherry-based additive
US7666859B2 (en) * 2006-09-08 2010-02-23 Norman Turkowitz Skin compositions containing hydrocortisone
US8623191B2 (en) * 2006-09-22 2014-01-07 Honeywell International Inc. Non-volatile addressable electronic paper with gray level capability

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670200A (en) * 1992-12-01 1997-09-23 Pleva; Raymond M. Cherry-containing meat product and method of making the same
US6103246A (en) * 1993-06-03 2000-08-15 Tisdale; Carrie J. Creams and lotions containing emu oil
US5472713A (en) * 1994-11-23 1995-12-05 Elf Resources, Inc. Therapeutic uses of emu oil
US5662921A (en) * 1994-11-23 1997-09-02 Elf Resources, Inc. Therapeutic uses of emu oil
US6407141B1 (en) * 1995-11-15 2002-06-18 Francis J. Hart Oxalic acid or oxalate compositions and methods for vascular disorders, diseases, and calcerous conditions
US6342208B1 (en) * 1996-08-02 2002-01-29 Plum Kerni Produktion A/S Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals
US20020055562A1 (en) * 1998-10-29 2002-05-09 Butuc S. Gina Gel compositions
US6881776B2 (en) * 1998-10-29 2005-04-19 Penreco Gel compositions
US6531126B2 (en) * 1999-08-26 2003-03-11 Ganeden Biotech, Inc. Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US6733751B2 (en) * 1999-08-26 2004-05-11 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations
US6534086B1 (en) * 2000-03-06 2003-03-18 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
US20030031724A1 (en) * 2001-05-16 2003-02-13 Frank Orthoefer Anti-inflammatory composition and method of using same
US20030175332A1 (en) * 2001-07-31 2003-09-18 Brown Harold G Methods of preventing or treating diseases and conditions using complex carbohydrates
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20050123479A1 (en) * 2002-03-01 2005-06-09 Antonio Ferrante Therapeutic properties of oils
US20050266064A1 (en) * 2004-05-29 2005-12-01 Mccarthy Kathryn J Cosmetic compositions and methods

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562976B2 (en) 2004-01-22 2013-10-22 University Of Miami Co-enzyme Q10 formulations and methods of use
US8586030B2 (en) 2004-01-22 2013-11-19 University Of Miami Co-enzyme Q10 formulations and methods of use
US8771680B2 (en) 2004-01-22 2014-07-08 University Of Miami Topical co-enzyme Q10 formulations and methods of use
US20090192126A1 (en) * 2006-04-12 2009-07-30 John Casey Oral Composition Comprising a Polyunsaturated Fatty Acid and Salicylic Acid for Obtaining an Antiinflammatory Effect in Skin
US8987329B2 (en) * 2006-04-12 2015-03-24 Conopco, Inc. Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
US10668028B2 (en) 2008-04-11 2020-06-02 Berg Llc Methods and use of inducing apoptosis in cancer cells
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US9896731B2 (en) 2009-05-11 2018-02-20 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US10351915B2 (en) 2009-05-11 2019-07-16 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10)
US11028446B2 (en) 2009-05-11 2021-06-08 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US10376477B2 (en) 2011-04-04 2019-08-13 Berg Llc Method of treating or preventing tumors of the central nervous system
US11452699B2 (en) 2011-04-04 2022-09-27 Berg Llc Method of treating or preventing tumors of the central nervous system
US20170304187A1 (en) * 2011-06-08 2017-10-26 Scott A. Weisenfluh EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections
US9968547B2 (en) * 2013-03-14 2018-05-15 3 In 1 Dental Pllc Compositions for treatment of xerostomia and for tooth treatment
US20150231060A1 (en) * 2013-03-14 2015-08-20 3 In 1 Dental Pllc Compositions for treatment of xerostomia and for tooth treatment
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
US9901542B2 (en) 2013-09-04 2018-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
US11298313B2 (en) 2013-09-04 2022-04-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10

Also Published As

Publication number Publication date
CA2574968A1 (fr) 2006-02-09
WO2006015119A3 (fr) 2006-03-16
EP1771185A4 (fr) 2009-09-23
US7939107B2 (en) 2011-05-10
JP2008508301A (ja) 2008-03-21
CN101065132A (zh) 2007-10-31
WO2006015119A2 (fr) 2006-02-09
AU2005269382A1 (en) 2006-02-09
EP1771185A2 (fr) 2007-04-11
CA2574968C (fr) 2014-05-20
RU2007103125A (ru) 2008-09-10
MX2007001098A (es) 2009-02-11
US20090258080A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
US7939107B2 (en) Emu oil and fruit composition
US11241406B2 (en) Compositions and methods for acutley raising nitric oxide levels
Javed Aloe vera gel in food, health products, and cosmetics industry
ES2254377T3 (es) Composiciones adecuadas para administracion oral y kits de las mismas para hidratar la piel de mamiferos.
US20070085058A1 (en) Nanoemulsion compositions and methods of use thereof
US8568806B2 (en) Stable and bioavailable compositions of isomers of lycopene for skin and hair
US20110060039A1 (en) Composition
KR101771702B1 (ko) 모링가 잎을 포함하는 항산화용 식품 조성물
US20140378543A1 (en) Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances
US20020192314A1 (en) Dietary supplement compositions
KR102178926B1 (ko) 발효 태반 조성물을 유효성분으로 하는 면역 증강 또는 항피로 조성물과 그의 용도
US9125430B2 (en) Stable and bioavailable compositions of isomers of carotenoids for skin and hair
KR101330411B1 (ko) 증숙 처리된 녹차 추출물을 유효성분으로 함유하는 아토피 피부염 개선용 조성물
JP4603269B2 (ja) 生理活性のない高分散型基質上で乾燥させた馬乳濃縮物の使用
KR102119307B1 (ko) 버드나무속 식물 추출물을 이용한 항염증용 조성물
KR20170045085A (ko) 피부 개선용 조성물 및 그의 용도
JP4809611B2 (ja) 脂肪細胞の脂肪蓄積阻害剤
KR20150120741A (ko) 감 껍질, 감 과육, 감잎 및 고욤잎의 혼합물을 유효성분으로 함유하는 아토피 피부염 예방 또는 개선용 조성물
Chabib et al. Therapeutic potential of cinnamon oil from Indonesia: Nanotechnology-essential oil
US20040131636A1 (en) Blood fluidity-improving health foods
KR20220105462A (ko) 모과 및 홍화씨 추출물을 포함하는 염증 질환 예방 또는 치료용 약학적 조성물
KR20210078834A (ko) 범꼬리 추출물을 이용한 항염증용 및 항알러지용 조성물
JP2023509324A (ja) アトピー皮膚炎疾患の予防、改善または治療用組成物
JP2023033042A (ja) Ｑｏｌ改善用組成物
JPS61293922A (ja) シミ改善料

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION